Related Experiment Video

Updated: Sep 28, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Antisense p53 transduction leads to overexpression of bcl-2 and dexamethasone resistance in multiple myeloma

Rajaraman Iyer1, LieMing Ding, Ramesh B Batchu

  • 1Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences and Central Arkansas VA Medical Center, Little Rock, AR 72205, USA.

Leukemia Research
|December 14, 2002
PubMed

Insights

Loss of p53 function in multiple myeloma cells promotes cancer growth and resistance to therapy by upregulating bcl-2. This study highlights p53

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Multiple myeloma is characterized by uncontrolled plasma cell growth due to failed apoptosis.
  • The role of p53 in myeloma cell apoptosis and drug resistance is not fully understood.

Purpose of the Study:

  • To investigate the impact of antisense p53 gene transduction on multiple myeloma cell behavior.
  • To elucidate the mechanisms underlying apoptosis resistance in multiple myeloma.

Main Methods:

  • Adeno-associated virus vector used for antisense p53 cDNA transduction in ARH77 myeloma cells.
  • Quantitative analysis of p53 mRNA, protein expression, and apoptosis levels.
  • Assessment of bcl-2, c-myc, and IL-6 gene expression.
  • Evaluation of dexamethasone resistance in transduced cells.

Main Results:

  • Antisense p53 transduction significantly reduced p53 expression and induced increased cell growth.
  • A five-fold upregulation of bcl-2 expression was observed in p53-deficient cells.
  • Apoptosis decreased from 15.6% in controls to 1.6% in p53as-transduced cells.
  • p53as cells overexpressing bcl-2 exhibited resistance to dexamethasone-induced cell death.

Conclusions:

  • Loss of p53 function is a key driver of multiple myeloma progression.
  • The bcl-2 pathway mediates p53-dependent apoptosis resistance in myeloma.
  • Targeting p53 or bcl-2 may offer therapeutic strategies for multiple myeloma.

More Related Videos

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...